Results 251 to 260 of about 653,368 (363)
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
Integrated Single-Cell Profiling of NK Cell Populations Across Solid Tumors
John Lozada
openalex +1 more source
Mechanotransduction of Piezo1 in the cancer microenvironment: implications for NK cell-based immunotherapy. [PDF]
Cui X, Zhang B, Zhao J, Tian H.
europepmc +1 more source
After liver transplantation, ischemia‐reperfusion injury is more severe in pericentral regions. Multiomic analyses of human grafts and mouse models identify FOXO1 activation in pericentral hepatocytes as an upstream driver of SAA secretion. SAA recruits and activates FPR2+ macrophages, amplifying local inflammation. Amilo‐5MER inhibits SAA bioactivity,
Feng Zhang +19 more
wiley +1 more source
Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo. [PDF]
Ling Z +6 more
europepmc +1 more source
ESCRT‐Mimetic Nanodegrader Targets STING for Anti‐Inflammatory Therapy
A nanoplatform‐enabled targeted protein degradation strategy is presented to regulate aberrant STING signaling. STING‐ATTEC induces selective autophagic degradation of STING via formation of a STING–ATTEC–LC3 ternary complex, while the cationic FA‐LNP+ system enhances LC3 generation and targeted delivery. Together, this synergistic approach efficiently
Fuyuan Zhou +9 more
wiley +1 more source
Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19. [PDF]
Ray U +11 more
europepmc +1 more source
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo +20 more
wiley +1 more source

